At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report ...
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...
In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.
Finally, blaming the pharmaceutical industry for high drug costs has historically been PBMs’ go-to defense. In a rebuttal to the FTC report issued in the summer, the PCMA criticized the ...
Pharmacy Benefit Managers (PBM) sit in the center of our prescription drug system, coordinating between insurance companies, ...
The Federal Trade Commission published a second interim staff report this week on the prescription drug middleman industry, which ...
In the report, the FTC said pharmacy benefit managers (PBMs), charge significant markups for cancer, HIV, and other critical ...
"Given the fact that there are states, counties, cities, school districts, pension funds, and other plaintiffs from all over ...
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying the major industry middlemen generate billions in revenue through ...
Dealbreaker on MSN13d
Pharmacy Benefit Managers Not Thrilled With FTC Report Finding Pharmacy Benefit Managers Raise Drug PricesThe pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission released ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback